A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
pharmaand GmbH
Study ID
NCT01891344
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.

Key Dates

Start date
Oct 30, 2013
Status verified
Jun 2023
Primary completion
Nov 5, 2019
Completion
Sep 28, 2021

Study Design

Enrollment
491 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ovarian cancer
    rucaparib

Primary Outcome Measure

Progression-free Survival (PFS) According to RECIST v1.1 in Molecularly-defined HRD (Homologous Recombination Deficiency) Subgroups (Part 1 of Study) [ Time Frame: Assessments every 8 weeks from C1D1 until disease progression, death or withdrawal of consent. After 18 months on study, assessments every 16 weeks. Total follow-up was up to approximately 3 years. ]

Locations (36)

FacilityCityStateZIPSite coordinators
Providence Alaska Medical CenterAnchorageAlaska99508-
University of Arizona Cancer CenterTucsonArizona85719-
Saint Jude Heritage Medical CenterFullertonCalifornia92835-
University of California Los AngelesLos AngelesCalifornia90404-
UC San DiegoSan DiegoCalifornia92093-
California Pacific Medical CenterSan FranciscoCalifornia94115-
University of California, San FranciscoSan FranciscoCalifornia94158-
Coastal Integrative Cancer CareSan Luis ObispoCalifornia93401-
Central Coast Medical OncologySanta MariaCalifornia93454-
Stanford UniversityStanfordCalifornia94305-
Rocky Mountain Cancer CentersLakewoodColorado80228-
Mayo Clinic JacksonvilleJacksonvilleFlorida32224-
Altus ResearchLake WorthFlorida33461-
University of Miami Hospital & Clinics Sylvester Comprehensive Cancer CenterMiamiFlorida33136-
Florida Hospital Cancer InstituteOrlandoFlorida32804-
UF Health Cancer CenterOrlandoFlorida32806-
Horizon BioAdvanceLafayetteIndiana47905-
Norton Cancer InstituteLouisvilleKentucky40241-
Johns Hopkins Kimmel Cancer CenterBaltimoreMaryland21287-
Dana-Farber Cancer InstituteBostonMassachusetts02115-
Massachusetts General HospitalBostonMassachusetts02114-
Mayo ClinicRochesterMinnesota55905-
Washington University School of MedicineSt LouisMissouri63110-
Comprehensive Cancer Centers of NevadaHendersonNevada89014-
Women's Cancer Care AssociatesAlbanyNew York12208-
Memorial Sloan-Kettering Cancer CenterNew YorkNew York10065-
New York University Langone Medical CenterNew YorkNew York10016-
Hope - A Woman's Cancer InstituteAshevilleNorth Carolina28006-
University of Cincinnati Physicians CompanyCincinnatiOhio45206-
The Ohio State University Wexner Medical CenterColumbusOhio43210-
University of OklahomaOklahoma CityOklahoma73019-
Fox Chase Cancer CenterPhiladelphiaPennsylvania19111-
University of PennsylvaniaPhiladelphiaPennsylvania19104-
UPMC Cancer CenterPittsburghPennsylvania15213-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030-
University of Washington - Seattle Cancer Care AllianceSeattleWashington98109-

Find similar trials in Anchorage, AK

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Providence Alaska Medical Center· Anchorage, AKUniversity of Arizona Cancer Center· Tucson, AZSaint Jude Heritage Medical Center· Fullerton, CAUniversity of California Los Angeles· Los Angeles, CAUC San Diego· San Diego, CACalifornia Pacific Medical Center· San Francisco, CA

Related Studies